Article Details

Driven by immunology and neuroscience drugs, AbbVie posts strong first-quarter 2022 - PharmaLive

Retrieved on: 2022-04-29 22:47:00

Tags for this article:

Click the tags to see associated articles and topics

Driven by immunology and neuroscience drugs, AbbVie posts strong first-quarter 2022 - PharmaLive. View article details on hiswai:

Excerpt

AbbVie is off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company's neuroscience platform that includes ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up